Dual GIP/GLP-1 agonist — the most effective FDA-approved weight-loss medication to date.
Tirzepatide (active ingredient in Mounjaro® and Zepbound®) is a dual GIP and GLP-1 receptor agonist. Head-to-head SURMOUNT and SURPASS trials show larger weight loss than semaglutide in most patient groups.
Weekly subcutaneous injection with staged dose escalation (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Monthly follow-ups with labs and body composition.
Dual agonism of GIP and GLP-1 receptors: enhanced insulin secretion, appetite suppression, delayed gastric emptying and improved insulin sensitivity.
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Common: nausea, diarrhea, decreased appetite. Screen for pancreatitis and gallbladder disease.
This page is educational and not medical advice. All VitaFlow protocols require evaluation by a licensed Florida physician.
Head-to-head trials show greater weight loss with Tirzepatide, though individual response varies.
GI symptoms are most common, typically improve over the first month at each dose.
Individualized — often 6–18 months with a maintenance strategy.
Our program pairs medication with protein and resistance-training guidance.
Coverage varies widely; transparent self-pay pricing available.
Meet with a VitaFlow physician to design a protocol tailored to your goals, biomarkers, and lifestyle.
